Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19565567 | 0.84 | PGR (0.38) | PGRALDH1A1SMN1; SMN2KEAP1MEN1 | |
| SCHEMBL279009 | 0.83 | ALDH1A1 (0.50) | PGRALDH1A1SMN1; SMN2KEAP1MEN1 | |
| SCHEMBL18802727 | 0.80 | MEN1 (0.42) | MEN1KMT2AIDO1NR3C2PTGS1 | |
| SCHEMBL2079427 | 0.79 | ALDH1A1 (0.42) | PGRALDH1A1SMN1; SMN2KEAP1AR | |
| SCHEMBL28201831 | 0.78 | PGR (0.51) | PGRALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL26751617 | 0.77 | PGR (0.35) | PGRALDH1A1KEAP1MEN1KMT2A | |
| SCHEMBL26751620 | 0.77 | PGR (0.35) | PGRALDH1A1KEAP1MEN1KMT2A | |
| SCHEMBL18701599 | 0.77 | PTGS1 (0.42) | ALDH1A1SMN1; SMN2MEN1KMT2ANR3C2 | |
| SCHEMBL18711606 | 0.77 | NR3C1 (0.44) | PGRMEN1KMT2ANR3C2NR3C1 | |
| SCHEMBL3291266 | 0.77 | SMN1; SMN2 (0.63) | PGRALDH1A1SMN1; SMN2FFAR4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293527-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230293527-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-11724987-B2 | Compositions and methods of treating retinal disease | ALDEYRA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230248727-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230248727-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-11583529-B2 | Treatment of inflammatory disorders | ALDEYRA THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| WO-2023278816-A1 | HETEROCYCLIC ALDEHYDE TRAPPING COMPOUNDS AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| US-20220133697-A1 | INJECTABLE FORMULATIONS | ALDEYRA THERAPEUTICS, INC. | 2022-05-05 | — | — | US | disclosed |
| US-20210353628-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2021-11-18 | — | — | US | disclosed |
| US-11040039-B2 | Treatment of inflammatory disorders | ALDEYRA THERAPEUTICS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-8940764-B2 | Compositions and methods of treating retinal disease | ALDEXA THERAPEUTICS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940721-B2 | Compositions and methods of treating retinal disease | ALDEXA THERAPEUTICS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20140374733-A1 | PHOTOELECTRIC CONVERSION ELEMENT, METHOD FOR USING THE SAME, IMAGING DEVICE, PHOTOSENSOR, AND COMPOUND | FUJIFILM CORPORATION (JP) | 2014-12-25 | — | — | US | disclosed |
| US-20140374733-A1 | PHOTOELECTRIC CONVERSION ELEMENT, METHOD FOR USING THE SAME, IMAGING DEVICE, PHOTOSENSOR, AND COMPOUND | FUJIFILM CORPORATION (JP) | 2014-12-25 | — | — | US | disclosed |
| US-20110263645-A1 | Compositions and Methods of Treating Retinal Disease | NEURON SYSTEMS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-7973025-B2 | Compositions and methods of treating retinal disease | NEURON SYSTEMS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| EP-2278969-A2 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2011-02-02 | — | — | EP | disclosed |
| WO-2010011375-A2 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20090182009-A1 | Compositions and methods of treating retinal disease | NEURON SYSTEMS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-20070135481-A1 | Compositions and methods of treating retinal disease | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182009-A1 | Compositions and methods of treating retinal disease | ALDH1A2, PLA2G2E, CLN6 | PGR 3677/4885ALDH1A1 725/4885SMN1; SMN2 507/4885 |
| US-11040039-B2 | Treatment of inflammatory disorders | TNF, NFKBIA, LTB4R2 | PGR 1434/4885ALDH1A1 1424/4885SMN1; SMN2 1964/4885 |
| US-11724987-B2 | Compositions and methods of treating retinal disease | ALDH1A2, PLA2G2E, CLN6 | PGR 3677/4885ALDH1A1 725/4885SMN1; SMN2 507/4885 |
| US-20230293527-A1 | TREATMENT OF INFLAMMATORY DISORDERS | TNF, NFKBIA, LTB4R2 | PGR 1434/4885ALDH1A1 1424/4885SMN1; SMN2 1964/4885 |
| US-11583529-B2 | Treatment of inflammatory disorders | TNF, NFKBIA, LTB4R2 | PGR 1434/4885ALDH1A1 1424/4885SMN1; SMN2 1964/4885 |
| US-20220133697-A1 | INJECTABLE FORMULATIONS | ALDH2, CLN6, ALDH1A1 | PGR 1924/4885ALDH1A1 3/4885SMN1; SMN2 20/4885 |
| US-20210353628-A1 | TREATMENT OF INFLAMMATORY DISORDERS | TNF, NFKBIA, LTB4R2 | PGR 1434/4885ALDH1A1 1424/4885SMN1; SMN2 1964/4885 |
| US-20070135481-A1 | Compositions and methods of treating retinal disease | ALDH1A2, PLA2G2E, CLN6 | PGR 3677/4885ALDH1A1 725/4885SMN1; SMN2 507/4885 |
| US-20230248727-A1 | TREATMENT OF INFLAMMATORY DISORDERS | TNF, NFKBIA, LTB4R2 | PGR 1434/4885ALDH1A1 1424/4885SMN1; SMN2 1964/4885 |
| US-20110263645-A1 | Compositions and Methods of Treating Retinal Disease | ALDH1A2, CLN6, PLA2G2E | PGR 3563/4885ALDH1A1 742/4885SMN1; SMN2 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.